BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02430532|
Recruitment Status : Terminated (Sponsor Decision)
First Posted : April 30, 2015
Results First Posted : March 27, 2017
Last Update Posted : April 26, 2017
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis, Secondary Progressive||Drug: dimethyl fumarate Other: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||58 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||January 2016|
Experimental: Dimethyl fumarate
BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
Drug: dimethyl fumarate
matched placebo capsule
BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
Drug: dimethyl fumarate
matched placebo capsule
- Time to Disability Progression Independent of Relapse [ Time Frame: Up to 108 weeks ]Time to onset of confirmed progression of disability is defined as 1 or more of the following criteria, confirmed at ≥ 6 months after start of treatment and at Week 108 using 1 or more of the following assessments: Expanded Disability Status Scale (EDSS) score increased from Baseline of ≥ 1 point if baseline EDSS ≤ 5.5, or ≥ 0.5 point if Baseline EDSS ≥ 6.0; Timed 25-Foot Walk (T25FW) ≥ 20% increase from Baseline in the time taken for the 25-foot walk; worsening on the 9-Hole Peg Test (9HPT; ≥ 20% increase from Baseline in the time taken for the 9HPT, confirmed in the same hand). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
- Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) [ Time Frame: Baseline, 2 years ]MSWS-12 is a participant self-assessment of walking limitations due to multiple sclerosis (MS) during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater negative impact on walking.
- Change From Baseline to Week 108 in ABILHAND Questionnaire Score [ Time Frame: Baseline, Week 108 ]The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. Participants fill in the 56-item questionnaire by estimating their own difficulty or ease in performing each of the 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability.
- Percentage Change From Baseline to Week 108 in Whole Brain Volume [ Time Frame: Baseline, Week 108 ]Whole brain volume is measured by magnetic resonance imaging (MRI).
- Change From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT) [ Time Frame: Baseline, Week 108 ]The SDMT measures the time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates a better outcome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 58 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Key Inclusion Criteria:
- Onset of SPMS at least 1 to 2 years prior to randomization. SPMS is defined as relapsing-remitting disease followed by progression of disability independent of or not explained by relapses.
- Have documented confirmed evidence of disease progression independent of clinical relapses over the 1 year prior to randomization.
- Have an Expanded Disability Status Scale score of 3.0 to 6.5, inclusive.
- Have a Multiple Sclerosis (MS) Severity Score of 4 or higher.
Key Exclusion Criteria:
- Have a diagnosis of relapsing remitting multiple sclerosis or primary progressive MS as defined by the revised McDonald criteria.
- Had a recent clinical relapse (within 3 months) prior to randomization.
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; serious or acute liver, kidney, or bone marrow dysfunction; uncontrolled diabetes; serious or acute psychiatric illness that would limit compliance with study requirements.
Note: Other protocol-defined Inclusion/Exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02430532
|United States, California|
|Long Beach, California, United States, 90806|
|San Francisco, California, United States, 94143|
|United States, Florida|
|Tampa, Florida, United States, 33634|
|Vero Beach, Florida, United States, 32960|
|United States, North Carolina|
|Charlotte, North Carolina, United States, 28207|
|United States, Pennsylvania|
|Willow Grove, Pennsylvania, United States, 19001|
|United States, Texas|
|Round Rock, Texas, United States, 78681|
|Bruxelles, Belgium, 1200|
|Brno, Czech Republic, 656 91|
|Hradec Kralove, Czech Republic, 500 05|
|Sittard-Geleen, Netherlands, 6162 BG|
|Gdansk, Poland, 80-803|
|Krakow, Poland, 31-505|
|Lodz, Poland, 93-121|
|Plewiska, Poland, 62-064|
|Poznan, Poland, 61-853|
|Banska Bystrica, Slovakia, 97404|
|Study Director:||Medical Director||Biogen|
|Other Study ID Numbers:||
2014-003021-18 ( EudraCT Number )
|First Posted:||April 30, 2015 Key Record Dates|
|Results First Posted:||March 27, 2017|
|Last Update Posted:||April 26, 2017|
|Last Verified:||March 2017|
Multiple Sclerosis, Chronic Progressive
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases
Physiological Effects of Drugs